menu
    • menu
    [{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piroxicam","moa":"COX-1","graph1":"Immunology","graph2":"Preclinical","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoform \/ Quotient Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nanoform \/ Quotient Sciences"},{"orgOrder":0,"company":"3PBiovian","sponsor":"Toleranzia","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"TOL2","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3PBiovian \/ Toleranzia","highestDevelopmentStatusID":"4","companyTruncated":"3PBiovian \/ Toleranzia"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanoform

                            Finland arrow
                            IFT FIRST
                            Not Confirmed

                            Nanoform

                            Finland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Quotient Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nanoform Initiates GMP Campaign for First-in-Human Trial of Nanoformed Drug by year End

                            Details : In the clinical trial, Nanoform will investigate the behavior of an oral immediate release (IR) nanoformed formulation of piroxicam, an anti-inflammatory drug.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 20, 2020

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Quotient Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            3PBiovian

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            3PBiovian

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOL2

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Toleranzia

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            3P Bio and Toleranzia Enter Orphan Drug Partnership

                            Details : Toleranzia’s innovative candidate (TOL2) is being developed for the treatment of the autoimmune neuromuscular disease Myasthenia Gravis (MG), an orphan disease, which has a major unmet medical need and a large market potential.

                            Product Name : TOL2

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : TOL2

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Toleranzia

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth